Changes in beta-adrenergic receptor subtypes in Alzheimer-type dementia

Area of Science:

• Neuroscience
• Pharmacology
• Neuropathology

Background:

• Beta-adrenergic receptors (β-ARs) are critical for neurotransmission and cognitive functions.
• Alterations in neurotransmitter systems are implicated in Alzheimer-type dementia (ATD).

Purpose of the Study:

• To investigate the distribution and concentration of beta 1- and beta 2-adrenergic receptor subtypes in human brain regions of individuals with and without ATD.
• To determine if ATD is associated with changes in β-AR subtype expression.

Main Methods:

• Ligand binding techniques were employed using autopsy-obtained brain samples from normal controls and ATD patients.
• Radioactive ligand [3H]dihydroalprenolol ([3H]DHA) and selective antagonists were used to quantify receptor subtypes.
• Hofstee plots were utilized to differentiate and quantify beta 1- and beta 2-adrenergic receptors.

Main Results:

• Both beta 1- and beta 2-adrenergic receptors were identified in various human brain regions.
• Total beta-adrenergic receptor concentration was significantly reduced in the thalamus of ATD brains compared to controls.
• Significant alterations in beta 1- and beta 2-adrenergic receptor concentrations were observed in specific brain regions, including the hippocampus, nucleus basalis of Meynert, thalamus, putamen, and cerebellar hemisphere in ATD patients.

Conclusions:

• The human brain expresses both beta 1- and beta 2-adrenergic receptor subtypes.
• Alzheimer-type dementia is associated with significant, region-specific changes in the concentrations of both beta 1- and beta 2-adrenergic receptors.
• These findings suggest a potential role for adrenergic receptor dysregulation in the pathophysiology of ATD.